Patel Chem Specialities reported a 30.6% year-on-year rise in revenue to ₹1,372.6 crore for the financial year ended March 31, 2026. Net profit increased by 18.7% to ₹125.5 crore, supported by strong domestic demand and the successful completion of its initial public offering.

The Ahmedabad-based manufacturer of pharmaceutical excipients saw its EBITDA grow by 20.1% to ₹188.9 crore. While revenue growth outpaced profit growth, the company maintained healthy operating earnings despite higher capital expenditure on new manufacturing facilities.

Financial Performance

Revenue from operations stood at ₹1,372.6 crore in FY26, compared to ₹1,050.9 crore in the previous year. The top-line expansion was driven by higher business volumes and stronger demand across its product portfolio, including sodium CMC and croscarmellose sodium.

Profit after tax rose from ₹105.7 crore to ₹125.5 crore. The pace of net profit growth remained moderated relative to revenue growth, reflecting the impact of increased operational scale and investments in infrastructure.

What the Numbers Show

EBITDA margin contracted to 13.6% in FY26 from 15.0% in FY25. This divergence between robust revenue growth and margin compression suggests that cost of materials or operating expenses grew faster than sales during the period. Despite the margin dip, absolute operating earnings improved significantly, indicating that volume leverage partially offset the efficiency drag.

Capital Raise and Expansion

The company listed on the BSE SME platform in August 2025, raising ₹58.8 crore through a fresh issue of 70 lakh shares at ₹84 per share. The IPO proceeds are being utilized primarily for capital expenditure, including a new manufacturing facility in Mehsana, Gujarat.

As of March 31, 2026, approximately ₹36.2 crore of the IPO proceeds remained unutilised and was parked in fixed deposits. The company has also completed the expansion of its Talod plant, increasing annual production capacity from 720 MT to 4,500 MT.

Balance Sheet Signals

Net worth surged to ₹995.0 crore from ₹354.0 crore in the prior year, driven by the equity infusion from the IPO. The debt-to-equity ratio improved sharply to 0.15 from 0.42, strengthening the financial position. Current assets grew significantly, with cash and cash equivalents rising to ₹365.9 crore from ₹64.1 crore, providing ample liquidity for future capex plans.

Patel Chem Specialties has scheduled a board meeting for Tuesday, September 1, 2026, to consider the approval of financial results for the fiscal year ended March 31, 2026.

The meeting will also address the re-appointment of Mrs. Anshu Bhupesh Patel as a director.

Agenda Details

The Board of Directors will transact the following businesses during the session:

• Re-appointment of Mrs. Anshu Bhupesh Patel (DIN: 02148403), who retires by rotation.
• Approval of the Directors Report for FY26.
• Fixing the date, time, and venue for the Annual General Meeting (AGM).
• Determining the record date for the AGM.
• Approval of the Draft Notice for the AGM.
• Appointment of a Scrutinizer for the e-voting process.
• Consideration of the Secretarial Auditor's Report for FY25-26.

The intimation was issued pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.